Sequential cisplatin-gemcitabine-docetaxel vs docetaxel-gemcitabine in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC):: Interim results of an ongoing phase II trial.

被引：0
|
作者：
Binder, D
Beinert, T
Schweisfurth, H
Grah, C
Temmesfeld-Wollbrock, B
Müller-Hagen, G
Schäper, C
Schürmann, D
Suttorp, N
机构：
[1] Med Klin Infektiolog, Berlin, Germany
[2] Klin Warternberg, Wartenberg, Germany
[3] Med Klin, Cottbus, Germany
[4] Med Klin Kardiol Pneumol, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7113
引用
收藏
页码：644S / 644S
页数：1
相关论文
共 50 条
  • [41] A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma
    Joaquín Casal Rubio
    S. Vázquez
    F. Vázquez
    M. Amenedo
    J. L. Fírvida
    J. R. Mel
    G. Huidobro
    E. Álvarez
    M. Lázaro
    G. Alonso
    I. Fernández
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 379 - 384
  • [42] Randomized phase II study of gemcitabine and carboplatin +/- sequential docetaxel in non-small cell lung cancer
    Hillerdal, Gunnar
    Sederholm, Christer
    Andersson, Kerstin
    LUNG CANCER, 2011, 71 (02) : 178 - 181
  • [43] Front-line treatment of advanced non-small cell lung cancer with docetaxel and Gemcitabine: A multicenter phase II trial
    Georgoulias, V
    Kourousis, C
    Kakolyris, S
    Dimopoulos, MA
    Papadakis, E
    Apostolopulou, F
    Agelidou, A
    Tzianni, V
    Sarra, E
    Vardakis, N
    ANNALS OF ONCOLOGY, 1998, 9 : 94 - 94
  • [44] Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
    Wilbur, H. Catherine
    Durham, Jennifer N.
    Lim, Su Jin
    Purtell, Katrina
    Bever, Katherine M.
    Laheru, Daniel A.
    De Jesus-Acosta, Ana
    Azad, Nilofer S.
    Wilt, Bradley
    Diaz, Luis A.
    Le, Dung T.
    Wang, Hao
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (08): : 1672 - 1677
  • [45] Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)
    Valerie Israel
    Scott T. Tagawa
    Terry Snyder
    Susan Jeffers
    Derek Raghavan
    Investigational New Drugs, 2004, 22 : 291 - 297
  • [46] Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer:: a lung cancer Galician group phase II study
    Casal, Joaquin
    Amenedo, Margarita
    Mel, Jose Ramon
    Anton, Luis Miguel
    Rodriguez-Lopez, Ruben
    Lopez-Lopez, Rafael
    Gonzalez-Ageitos, Ana
    Castellanos, Javier
    Constenla, Manuel
    Tisaire, Jose L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (05) : 725 - 732
  • [47] Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study
    Joaquín Casal
    Margarita Amenedo
    José Ramón Mel
    Luis Miguel Antón
    Rubén Rodríguez-López
    Rafael López-López
    Ana González-Ageitos
    Javier Castellanos
    Manuel Constenla
    José L. Tisaire
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 725 - 732
  • [48] First-line chemotherapy with sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer (NSCLC) patients: a multicenter phase II study
    Tibaldi, C.
    Vasile, E.
    Lo Dico, M.
    Antonuzzo, A.
    Di Marsico, R.
    Tartarelli, G.
    Fabbri, A.
    Mazzoni, E.
    Andreuccetti, M.
    Falcone, A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 176 - 176
  • [49] Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC)
    Rubinsak, J. R.
    Spigel, D. R.
    Hainsworth, J. D.
    Webb, C.
    Inhorn, R. C.
    Infante, J. R.
    Yardley, D. A.
    Burris, H. A., III
    Vazquez, E. R.
    Greco, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)
    Israel, V
    Tagawa, ST
    Snyder, T
    Jeffers, S
    Raghavan, D
    INVESTIGATIONAL NEW DRUGS, 2004, 22 (03) : 291 - 297
12345